Amphista Therapeutics Welcomes Paul Medeiros as Chief Business Officer
Amphista Therapeutics is pleased to announce the appointment of Paul Medeiros as its Chief Business Officer (CBO). This strategic move reflects the company's commitment to advancing its innovative portfolio of next-generation Targeted Glue™ protein degrader therapeutics and enhancing overall corporate development.
Experience and Leadership in Biopharma
Paul Medeiros comes with extensive experience in the biopharmaceutical arena. He has held various executive positions within both commercial and pre-commercial organizations, showcasing a successful track record in biopharma strategy, portfolio development, and corporate advancement. His experience is expected to be pivotal for Amphista as it embarks on its next growth phase.
Notable Achievements Prior to Joining Amphista
Before joining Amphista Therapeutics, Paul served as President and CEO of Q-State Biosciences, where he achieved significant milestones, including the successful sale of the company. His expertise will be instrumental in shaping Amphista's strategic initiatives and ensuring the successful advancement of its first Targeted Glue™ therapeutics into clinical trials.
Vision for the Future
Speaking on his new role, Paul Medeiros expressed his excitement, stating that he is thrilled to join Amphista at a critical juncture for the company. He emphasized the strength of Amphista's proprietary chemistry and its unique Eclipsys™ platform, which offers exceptional opportunities to advance therapeutic protein degradation mechanisms that exceed the traditional cereblon and VHL approaches.
Endorsements from Leadership
Antony Mattessich, the Chief Executive Officer of Amphista, voiced his enthusiasm for Paul's appointment, highlighting his deep industry knowledge and experience. Mattessich asserted that Paul’s leadership will be essential in maximizing Amphista's capabilities as a developer of rationally-designed Targeted Glue™ therapeutics that tackle disease-causing proteins more effectively.
About Amphista Therapeutics
Amphista Therapeutics is dedicated to revolutionizing the treatment landscape for patients suffering from challenging conditions, such as cancer and neurodegenerative diseases. By leveraging its proprietary Eclipsys™ platform, the company aims to develop next-generation targeted protein degradation (TPD) medicines that demonstrate enhanced drug-like properties and innovative mechanisms.
Commitment to Innovation and Patient Care
The company's portfolio is designed to potentially deliver therapeutics that stand out as first- or best-in-class, overcoming the inherent limitations of existing agents like CRBN and VHL. Amphista was co-founded by Advent Life Sciences and is backed by a distinguished group of investors, ensuring robust support for its innovative endeavors.
Contact Information
For further inquiries, you can reach out to Amphista Therapeutics. Below is the contact information:
Amphista Therapeutics Contact
John Goodall
Email: Info@amphista.com
ICR Healthcare Information
Amber Fennell, Namrata Taak, Emily Johnson
Email: Amphista@icrhealthcare.com
Tel: +44 (0)20 3709 5813
Frequently Asked Questions
What is Amphista Therapeutics focused on?
Amphista Therapeutics is dedicated to developing innovative protein degradation medicines for severe diseases, including cancer and neurodegenerative disorders.
Who has been appointed as the Chief Business Officer?
Paul Medeiros has been appointed as the Chief Business Officer of Amphista Therapeutics.
What is the Eclipsys™ platform?
The Eclipsys™ platform is Amphista's proprietary technology that enables the development of advanced, bifunctional Targeted Glue therapeutics with superior drug-like properties.
Where was Paul Medeiros employed before joining Amphista?
Before Amphista, Paul Medeiros was the President and CEO of Q-State Biosciences.
How does Amphista aim to differentiate its therapeutics?
Amphista aims to provide first- and best-in-class therapeutics through its unique approaches that go beyond CRBN and VHL-based methods.
